NO305660B1 - DNA-sekvens som koder for et human-aktivert protein C, rekombinant ekspresjonsvektor som omfatter DNA-sekvensen, pattedyrceller transfektert med ekspresjonsvektoren og fremgangsmÕte for fremstilling av human-aktivert protein C - Google Patents

DNA-sekvens som koder for et human-aktivert protein C, rekombinant ekspresjonsvektor som omfatter DNA-sekvensen, pattedyrceller transfektert med ekspresjonsvektoren og fremgangsmÕte for fremstilling av human-aktivert protein C Download PDF

Info

Publication number: NO305660B1
Authority: NO; Norway
Prior art keywords: protein; dna; human; activated protein; sequence
Prior art date: 1985-06-27

Application number

NO862601A

Other languages

English (en)

Norwegian (no)

Other versions

NO862601L (no

NO862601D0 (no

Inventor

Mark J Murray

Kathleen L Berkner

Donald Cameron Foster

Earl W Davie

Original Assignee

Zymogenetics Inc

Univ Washington

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-06-27

Filing date

1986-06-27

Publication date

1999-07-05

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27115147&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO305660(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1985-08-15 Priority claimed from US06/766,109 external-priority patent/US4968626A/en

1986-06-27 Application filed by Zymogenetics Inc, Univ Washington filed Critical Zymogenetics Inc

1986-06-27 Publication of NO862601D0 publication Critical patent/NO862601D0/no

1986-12-29 Publication of NO862601L publication Critical patent/NO862601L/no

1999-07-05 Publication of NO305660B1 publication Critical patent/NO305660B1/no

Links

101800004937 Protein C Proteins 0.000 title claims abstract description 112
101800001700 Saposin-D Proteins 0.000 title claims abstract description 106
229960000856 protein c Drugs 0.000 title claims abstract description 106
102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 title claims abstract 11
239000013604 expression vector Substances 0.000 title claims description 30
108091028043 Nucleic acid sequence Proteins 0.000 title claims description 20
210000004962 mammalian cell Anatomy 0.000 title claims description 13
238000004519 manufacturing process Methods 0.000 title claims description 8
238000003259 recombinant expression Methods 0.000 title claims 2
108090000623 proteins and genes Proteins 0.000 claims abstract description 66
102000004169 proteins and genes Human genes 0.000 claims abstract description 42
238000000034 method Methods 0.000 claims abstract description 28
239000002773 nucleotide Substances 0.000 claims abstract description 23
125000003729 nucleotide group Chemical group 0.000 claims abstract description 23
230000008488 polyadenylation Effects 0.000 claims abstract description 22
230000010354 integration Effects 0.000 claims abstract 3
108020004414 DNA Proteins 0.000 claims description 62
210000004027 cell Anatomy 0.000 claims description 53
230000014509 gene expression Effects 0.000 claims description 27
229930003448 Vitamin K Natural products 0.000 claims description 11
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 11
235000019168 vitamin K Nutrition 0.000 claims description 11
239000011712 vitamin K Substances 0.000 claims description 11
150000003721 vitamin K derivatives Chemical class 0.000 claims description 11
229940046010 vitamin k Drugs 0.000 claims description 11
239000003550 marker Substances 0.000 claims description 10
238000013518 transcription Methods 0.000 claims description 9
230000035897 transcription Effects 0.000 claims description 9
230000008569 process Effects 0.000 claims description 8
101800001401 Activation peptide Proteins 0.000 claims description 7
102400000069 Activation peptide Human genes 0.000 claims description 7
102100023804 Coagulation factor VII Human genes 0.000 claims description 7
229940012413 factor vii Drugs 0.000 claims description 7
102100022641 Coagulation factor IX Human genes 0.000 claims description 6
108010023321 Factor VII Proteins 0.000 claims description 6
229960004222 factor ix Drugs 0.000 claims description 6
108010076282 Factor IX Proteins 0.000 claims description 5
108010094028 Prothrombin Proteins 0.000 claims description 5
102100027378 Prothrombin Human genes 0.000 claims description 5
229940039716 prothrombin Drugs 0.000 claims description 5
102000005701 Calcium-Binding Proteins Human genes 0.000 claims description 4
108010045403 Calcium-Binding Proteins Proteins 0.000 claims description 4
229940012426 factor x Drugs 0.000 claims description 4
108010014173 Factor X Proteins 0.000 claims description 3
241000699800 Cricetinae Species 0.000 claims description 2
125000003275 alpha amino acid group Chemical group 0.000 claims 2
210000003292 kidney cell Anatomy 0.000 claims 1
239000013612 plasmid Substances 0.000 abstract description 60
239000002299 complementary DNA Substances 0.000 abstract description 50
101500025568 Homo sapiens Saposin-D Proteins 0.000 abstract description 22
229940100689 human protein c Drugs 0.000 abstract description 22
230000000694 effects Effects 0.000 abstract description 17
239000013598 vector Substances 0.000 abstract description 16
230000004071 biological effect Effects 0.000 abstract description 8
102000017975 Protein C Human genes 0.000 description 94
239000012634 fragment Substances 0.000 description 65
235000018102 proteins Nutrition 0.000 description 34
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 31
150000001413 amino acids Chemical group 0.000 description 26
108091026890 Coding region Proteins 0.000 description 24
235000001014 amino acid Nutrition 0.000 description 20
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
239000000872 buffer Substances 0.000 description 17
108090000765 processed proteins & peptides Proteins 0.000 description 17
102100024746 Dihydrofolate reductase Human genes 0.000 description 15
108020001096 dihydrofolate reductase Proteins 0.000 description 15
108700024394 Exon Proteins 0.000 description 14
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 12
108091034117 Oligonucleotide Proteins 0.000 description 11
108091092195 Intron Proteins 0.000 description 10
238000003776 cleavage reaction Methods 0.000 description 10
238000010276 construction Methods 0.000 description 10
108091008146 restriction endonucleases Proteins 0.000 description 10
241000588724 Escherichia coli Species 0.000 description 9
238000000246 agarose gel electrophoresis Methods 0.000 description 9
238000012545 processing Methods 0.000 description 9
230000007017 scission Effects 0.000 description 9
102000004506 Blood Proteins Human genes 0.000 description 8
108010017384 Blood Proteins Proteins 0.000 description 8
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
230000001419 dependent effect Effects 0.000 description 8
238000002703 mutagenesis Methods 0.000 description 8
231100000350 mutagenesis Toxicity 0.000 description 8
102100033195 DNA ligase 4 Human genes 0.000 description 7
101000927810 Homo sapiens DNA ligase 4 Proteins 0.000 description 7
108091092724 Noncoding DNA Proteins 0.000 description 7
230000003197 catalytic effect Effects 0.000 description 7
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 7
239000002609 medium Substances 0.000 description 7
230000004913 activation Effects 0.000 description 6
238000003556 assay Methods 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
238000003780 insertion Methods 0.000 description 6
230000037431 insertion Effects 0.000 description 6
239000000203 mixture Substances 0.000 description 6
239000000047 product Substances 0.000 description 6
238000011144 upstream manufacturing Methods 0.000 description 6
108091003079 Bovine Serum Albumin Proteins 0.000 description 5
108010016626 Dipeptides Proteins 0.000 description 5
241001131785 Escherichia coli HB101 Species 0.000 description 5
108010074105 Factor Va Proteins 0.000 description 5
241000701109 Human adenovirus 2 Species 0.000 description 5
230000004927 fusion Effects 0.000 description 5
239000000499 gel Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
239000002244 precipitate Substances 0.000 description 5
229920000936 Agarose Polymers 0.000 description 4
241000283690 Bos taurus Species 0.000 description 4
108010061982 DNA Ligases Proteins 0.000 description 4
102000012410 DNA Ligases Human genes 0.000 description 4
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 4
229920001213 Polysorbate 20 Polymers 0.000 description 4
229940096437 Protein S Drugs 0.000 description 4
102000029301 Protein S Human genes 0.000 description 4
108010066124 Protein S Proteins 0.000 description 4
108020005067 RNA Splice Sites Proteins 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
108090000190 Thrombin Proteins 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
230000031018 biological processes and functions Effects 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000001720 carbohydrates Chemical class 0.000 description 4
238000010367 cloning Methods 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
230000003480 fibrinolytic effect Effects 0.000 description 4
230000006870 function Effects 0.000 description 4
238000009396 hybridization Methods 0.000 description 4
229940065638 intron a Drugs 0.000 description 4
210000004185 liver Anatomy 0.000 description 4
229910001629 magnesium chloride Inorganic materials 0.000 description 4
230000001404 mediated effect Effects 0.000 description 4
108020004999 messenger RNA Proteins 0.000 description 4
229960000485 methotrexate Drugs 0.000 description 4
150000003904 phospholipids Chemical class 0.000 description 4
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 4
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 4
230000004481 post-translational protein modification Effects 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
230000006337 proteolytic cleavage Effects 0.000 description 4
239000000523 sample Substances 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
101500025565 Bos taurus Saposin-D Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
108020004705 Codon Proteins 0.000 description 3
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
241001135569 Human adenovirus 5 Species 0.000 description 3
NPBGTPKLVJEOBE-IUCAKERBSA-N Lys-Arg Chemical group NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=N NPBGTPKLVJEOBE-IUCAKERBSA-N 0.000 description 3
108700026244 Open Reading Frames Proteins 0.000 description 3
238000012300 Sequence Analysis Methods 0.000 description 3
102000012479 Serine Proteases Human genes 0.000 description 3
108010022999 Serine Proteases Proteins 0.000 description 3
238000002105 Southern blotting Methods 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
230000009471 action Effects 0.000 description 3
125000000539 amino acid group Chemical group 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
239000003146 anticoagulant agent Substances 0.000 description 3
CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
229940098773 bovine serum albumin Drugs 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
239000001506 calcium phosphate Substances 0.000 description 3
229910000389 calcium phosphate Inorganic materials 0.000 description 3
235000011010 calcium phosphates Nutrition 0.000 description 3
230000015271 coagulation Effects 0.000 description 3
238000005345 coagulation Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
239000012636 effector Substances 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
238000011534 incubation Methods 0.000 description 3
230000014508 negative regulation of coagulation Effects 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
230000017854 proteolysis Effects 0.000 description 3
229960004072 thrombin Drugs 0.000 description 3
238000001890 transfection Methods 0.000 description 3
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 3
239000001226 triphosphate Substances 0.000 description 3
235000011178 triphosphate Nutrition 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
YYLQUHNPNCGKJQ-NHYDCYSISA-N (3R)-3-hydroxy-L-aspartic acid Chemical compound OC(=O)[C@@H](N)[C@@H](O)C(O)=O YYLQUHNPNCGKJQ-NHYDCYSISA-N 0.000 description 2
OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 2
102000004594 DNA Polymerase I Human genes 0.000 description 2
108010017826 DNA Polymerase I Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108700028146 Genetic Enhancer Elements Proteins 0.000 description 2
101001125402 Homo sapiens Vitamin K-dependent protein C Proteins 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
108010001014 Plasminogen Activators Proteins 0.000 description 2
102000001938 Plasminogen Activators Human genes 0.000 description 2
108091036407 Polyadenylation Proteins 0.000 description 2
201000005660 Protein C Deficiency Diseases 0.000 description 2
101710132580 Protein C' Proteins 0.000 description 2
LOUPRKONTZGTKE-WZBLMQSHSA-N Quinine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-WZBLMQSHSA-N 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
108020005038 Terminator Codon Proteins 0.000 description 2
108010022394 Threonine synthase Proteins 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
241000700605 Viruses Species 0.000 description 2
102100029477 Vitamin K-dependent protein C Human genes 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002429 anti-coagulating effect Effects 0.000 description 2
229940127219 anticoagulant drug Drugs 0.000 description 2
229940006612 barium citrate Drugs 0.000 description 2
PAVWOHWZXOQYDB-UHFFFAOYSA-H barium(2+);2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ba+2].[Ba+2].[Ba+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PAVWOHWZXOQYDB-UHFFFAOYSA-H 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000027455 binding Effects 0.000 description 2
229910001424 calcium ion Inorganic materials 0.000 description 2
244000309466 calf Species 0.000 description 2
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
230000009849 deactivation Effects 0.000 description 2
231100000673 dose–response relationship Toxicity 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
239000003623 enhancer Substances 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
238000001976 enzyme digestion Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000012894 fetal calf serum Substances 0.000 description 2
239000012737 fresh medium Substances 0.000 description 2
230000006251 gamma-carboxylation Effects 0.000 description 2
230000002068 genetic effect Effects 0.000 description 2
208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002955 isolation Methods 0.000 description 2
238000005304 joining Methods 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000000463 material Substances 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
231100000219 mutagenic Toxicity 0.000 description 2
230000003505 mutagenic effect Effects 0.000 description 2
229940127126 plasminogen activator Drugs 0.000 description 2
231100000614 poison Toxicity 0.000 description 2
239000002574 poison Substances 0.000 description 2
229920001184 polypeptide Polymers 0.000 description 2
230000020964 regulation of blood coagulation Effects 0.000 description 2
230000003362 replicative effect Effects 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000009962 secretion pathway Effects 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000009466 transformation Effects 0.000 description 2
125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
101150111062 C gene Proteins 0.000 description 1
108091028026 C-DNA Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
235000001258 Cinchona calisaya Nutrition 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
102000053602 DNA Human genes 0.000 description 1
230000004544 DNA amplification Effects 0.000 description 1
230000008836 DNA modification Effects 0.000 description 1
238000001712 DNA sequencing Methods 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
101100128281 Enterobacteria phage T4 rIII gene Proteins 0.000 description 1
102000010911 Enzyme Precursors Human genes 0.000 description 1
108010062466 Enzyme Precursors Proteins 0.000 description 1
YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 1
241001524679 Escherichia virus M13 Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108010048049 Factor IXa Proteins 0.000 description 1
108010054265 Factor VIIa Proteins 0.000 description 1
108010074860 Factor Xa Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
102000003886 Glycoproteins Human genes 0.000 description 1
108090000288 Glycoproteins Proteins 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101100273566 Humulus lupulus CCL10 gene Proteins 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
108010077971 Plasminogen Inactivators Proteins 0.000 description 1
102000010752 Plasminogen Inactivators Human genes 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010076504 Protein Sorting Signals Proteins 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
108091036333 Rapid DNA Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
241000702208 Shigella phage SfX Species 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
102100026966 Thrombomodulin Human genes 0.000 description 1
108010079274 Thrombomodulin Proteins 0.000 description 1
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 1
102100033571 Tissue-type plasminogen activator Human genes 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
108091034131 VA RNA Proteins 0.000 description 1
101710181904 Venom factor Proteins 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
241001672648 Vieira Species 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001594 aberrant effect Effects 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000012190 activator Substances 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
230000003321 amplification Effects 0.000 description 1
239000012491 analyte Substances 0.000 description 1
230000002823 anti-activator Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
229910001626 barium chloride Inorganic materials 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000003686 blood clotting factor concentrate Substances 0.000 description 1
AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000008859 change Effects 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
230000035602 clotting Effects 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
239000003636 conditioned culture medium Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000006911 enzymatic reaction Methods 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
108091005606 gamma-carboxylated proteins Proteins 0.000 description 1
208000016361 genetic disease Diseases 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
239000006166 lysate Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000035800 maturation Effects 0.000 description 1
230000005541 medical transmission Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
108091027963 non-coding RNA Proteins 0.000 description 1
102000042567 non-coding RNA Human genes 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
239000002777 nucleoside Substances 0.000 description 1
-1 nucleoside triphosphates Chemical class 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
229940127216 oral anticoagulant drug Drugs 0.000 description 1
239000008188 pellet Substances 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
239000002797 plasminogen activator inhibitor Substances 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
238000002731 protein assay Methods 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
229960000948 quinine Drugs 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
230000025078 regulation of biosynthetic process Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
108010038196 saccharide-binding proteins Proteins 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
239000006152 selective media Substances 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
239000003998 snake venom Substances 0.000 description 1
108010026668 snake venom protein C activator Proteins 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
210000001082 somatic cell Anatomy 0.000 description 1
230000000392 somatic effect Effects 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
238000010561 standard procedure Methods 0.000 description 1
239000007858 starting material Substances 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000013519 translation Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
KNFMYSSYYFKXDE-UHFFFAOYSA-K trisodium;benzenecarboximidamide;phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O.NC(=N)C1=CC=CC=C1 KNFMYSSYYFKXDE-UHFFFAOYSA-K 0.000 description 1
108010087967 type I signal peptidase Proteins 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
238000004804 winding Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6464—Protein C (3.4.21.69)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
General Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physics & Mathematics (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Diabetes (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Plant Pathology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Saccharide Compounds (AREA)

NO862601A 1985-06-27 1986-06-27 DNA-sekvens som koder for et human-aktivert protein C, rekombinant ekspresjonsvektor som omfatter DNA-sekvensen, pattedyrceller transfektert med ekspresjonsvektoren og fremgangsmÕte for fremstilling av human-aktivert protein C NO305660B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US74960085A	1985-06-27	1985-06-27
US06/766,109 US4968626A (en)	1985-08-15	1985-08-15	DNA sequence coding for protein C

Publications (3)

Publication Number	Publication Date
NO862601D0 NO862601D0 (no)	1986-06-27
NO862601L NO862601L (no)	1986-12-29
NO305660B1 true NO305660B1 (no)	1999-07-05

Family

ID=27115147

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO862601A NO305660B1 (no)	1985-06-27	1986-06-27	DNA-sekvens som koder for et human-aktivert protein C, rekombinant ekspresjonsvektor som omfatter DNA-sekvensen, pattedyrceller transfektert med ekspresjonsvektoren og fremgangsmÕte for fremstilling av human-aktivert protein C

Country Status (7)

Country	Link
EP (1)	EP0215548B2 (fr)
JP (2)	JP2614848B2 (fr)
AT (1)	ATE93272T1 (fr)
CA (1)	CA1341228C (fr)
DE (1)	DE3688900T3 (fr)
DK (1)	DK175574B1 (fr)
NO (1)	NO305660B1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4959318A (en) *	1985-06-27	1990-09-25	Zymogenetics, Inc.	Expression of protein C
US5550036A (en) *	1986-04-09	1996-08-27	Eli Lilly And Company	Method for co-amplification of human protein C genes in human cells
USH1148H (en)	1987-04-17	1993-03-02		Method of separating activated human protein C
EP0296413A2 (fr) *	1987-06-12	1988-12-28	Hoechst Japan Limited	Protéine C hybride et sa méthode de préparation
US5084274A (en) *	1987-11-17	1992-01-28	Scripps Clinic And Research Foundation	Inhibition of arterial thrombotic occlusion or thromboembolism
US4992373A (en) *	1987-12-04	1991-02-12	Eli Lilly And Company	Vectors and compounds for direct expression of activated human protein C
US5196322A (en) *	1987-12-28	1993-03-23	Eli Lilly And Company	Vectors and compounds for expression of zymogen forms of human protein C
JP2728240B2 (ja) *	1988-07-26	1998-03-18	ヘキスト薬品工業株式会社	ヒトプロテインｃ変異体及びその製造方法
CA1332049C (fr) *	1988-10-07	1994-09-20	Eli Lilly And Company	Expression eucaryotique
WO1991002065A1 (fr) *	1989-08-11	1991-02-21	Zymogenetics, Inc.	Procedes de culture de cellules pour la production de proteine c activee
JP2774156B2 (ja) *	1989-09-05	1998-07-09	帝人株式会社	ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
JP2774163B2 (ja) *	1989-11-14	1998-07-09	帝人株式会社	ヒトプロテインｃ様活性を有する蛋白
AU7168591A (en) *	1989-12-29	1991-07-24	Zymogenetics Inc.	Hybrid protein c
US5358932A (en) *	1989-12-29	1994-10-25	Zymogenetics, Inc.	Hybrid protein C
IL97311A0 (en) *	1990-02-23	1992-05-25	Lilly Co Eli	Vectors and compounds for expression of glycosylation mutants of human protein c
US5270178A (en) *	1990-02-23	1993-12-14	Eli Lilly And Company	Vectors and compounds for expression of zymogen forms of human protein C
AT402263B (de)	1991-06-20	1997-03-25	Immuno Ag	Pharmazeutische präparation enthaltend eine thrombolytisch wirkende substanz
JPH08508875A (ja) *	1992-05-01	1996-09-24	帝人株式会社	蛋白分泌細胞の流加回分培養法
DE4320294A1 (de) *	1993-06-18	1994-12-22	Immuno Ag	Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US5561053A (en) *	1994-08-05	1996-10-01	Genentech, Inc.	Method for selecting high-expressing host cells
CA2391651A1 (fr) *	1999-11-19	2001-05-25	Eli Lilly And Company	Derives de proteine c
JP2009502118A (ja) *	2005-05-24	2009-01-29	アベスタゲンリミテッド	敗血症治療のための組み換え活性化ヒトタンパク質ｃを生成する方法
WO2014064580A1 (fr)	2012-10-23	2014-05-01	Koninklijke Philips N.V.	Système de mesure de stress

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8327860D0 (en) *	1983-10-18	1983-11-16	Fujisawa Pharmaceutical Co	Monoclonal antiprotein c antibody
US4775624A (en) *	1985-02-08	1988-10-04	Eli Lilly And Company	Vectors and compounds for expression of human protein C

1986
- 1986-06-26 DE DE3688900T patent/DE3688900T3/de not_active Expired - Lifetime
- 1986-06-26 CA CA000512483A patent/CA1341228C/fr not_active Expired - Fee Related
- 1986-06-26 EP EP86304970A patent/EP0215548B2/fr not_active Expired - Lifetime
- 1986-06-26 AT AT86304970T patent/ATE93272T1/de not_active IP Right Cessation
- 1986-06-27 JP JP61151303A patent/JP2614848B2/ja not_active Expired - Lifetime
- 1986-06-27 DK DK198603085A patent/DK175574B1/da not_active IP Right Cessation
- 1986-06-27 NO NO862601A patent/NO305660B1/no not_active IP Right Cessation
1996
- 1996-07-09 JP JP8179612A patent/JP2688407B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP0215548B1 (fr)	1993-08-18
DK308586A (da)	1986-12-28
ATE93272T1 (de)	1993-09-15
EP0215548B2 (fr)	1998-01-07
DK308586D0 (da)	1986-06-27
JPS62111690A (ja)	1987-05-22
DK175574B1 (da)	2004-12-13
NO862601L (no)	1986-12-29
JPH09107976A (ja)	1997-04-28
DE3688900D1 (de)	1993-09-23
JP2688407B2 (ja)	1997-12-10
NO862601D0 (no)	1986-06-27
DE3688900T3 (de)	1998-06-10
CA1341228C (fr)	2001-05-15
JP2614848B2 (ja)	1997-05-28
EP0215548A1 (fr)	1987-03-25
DE3688900T2 (de)	1993-12-09

Legal Events

Date	Code	Title	Description
2006-08-21	MK1K	Patent expired

Publication	Publication Date	Title
US4959318A (en)	1990-09-25	Expression of protein C
EP0215548B2 (fr)	1998-01-07	Expression de protéine C
US5516650A (en)	1996-05-14	Production of activated protein C
US5225537A (en)	1993-07-06	Methods for producing hybrid phospholipid-binding proteins
EP0319312B1 (fr)	1993-11-03	Vecteurs et composés pour l'expression directe de protéine C humaine activée
DK175616B1 (da)	2004-12-27	Ekspression af faktor VII aktiviteter i pattedyrceller
FI104734B (fi)	2000-03-31	Menetelmä plasminogeenin valmistamiseksi
JP2575369B2 (ja)	1997-01-22	新規ペプチドのプラスミノ−ゲンアクチベ−タ−
EP0143081A2 (fr)	1985-05-29	Synthèse d'activateur du plasminogene tissulaire(TPA) par levure
US5302529A (en)	1994-04-12	Plasmid coding for human protein C
WO1991012320A1 (fr)	1991-08-22	Proteine c activee a chaine legere tronquee
EP0485504B1 (fr)	1993-12-01	Procedes de culture de cellules pour la production de proteine c activee
USRE38981E1 (en)	2006-02-14	DNA sequence coding for protein C
WO1991009951A2 (fr)	1991-07-11	Proteine c recombinee a chaine legere tronquee